Diagnostic and Therapeutic Potential of Exosomes in Cancer: The Beginning of a New Tale?

Journal of Cellular Physiology

Volumn 232, Issue 12, 2017, Pages 3251-3260

  Mirzaei, Hamed ^a   Sahebkar, Amirhossein ^a   Jaafari, Mahmoud Reza ^b   Goodarzi, Mohammad ^c   Mirzaei, Hamid Reza ^d  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; TUMOR MARKER;

ANGIOGENESIS; CANCER DIAGNOSIS; CANCER THERAPY; CARCINOGENESIS; EXOSOME; HUMAN; MALIGNANT NEOPLASM; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR ESCAPE; TUMOR GROWTH; ANIMAL; CHEMISTRY; DISEASE EXACERBATION; DRUG RESISTANCE; IMMUNE EVASION; NEOPLASM; PATHOLOGY;

ANIMALS; BIOMARKERS, TUMOR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EXOSOMES; HUMANS; IMMUNE EVASION; NEOPLASMS;

EID: 85018699233     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25739     Document Type: Review

References (134)

1. Abd Elmageed ZY, Yang Y, Thomas R, Ranjan M, Mondal D, Moroz K, Fang Z, Rezk BM, Moparty K, Sikka SC. 2014. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells 32:983–997.
2. Aga M, Bentz GL, Raffa S, Torrisi MR, Kondo S, Wakisaka N, Yoshizaki T, Pagano JS, Shackelford J. 2014. Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene 33:4613–4622.
3. Akers JC, Gonda D, Kim R, Carter BS, Chen CC. 2013a. Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol 113:1–11.
4. Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S, Kalinina J, Hua W, Kesari S, Mao Y, Breakefield XO, Hochberg FH, Van Meir EG, Carter BS, Chen CC. 2013b. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): A platform for glioblastoma biomarker development. PLoS ONE 8:e78115.
5. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. 2008. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10:619–624.
6. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. 2011. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29:341–345.
7. Arabpour M, Mohammadparast S, Maftouh M, ShahidSales S, Moieni S, Akbarzade H, Mirhafez S, Parizadeh S, Hassanian S, Avan A. 2016. Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in gastric cancer: Current status and future perspectives. Curr Med Chem 23:4135–4150.
8. Atay S, Banskota S, Crow J, Sethi G, Rink L, Godwin AK. 2014. Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc Natl Acad Sci USA 111:711–716.
9. Battke C, Ruiss R, Welsch U, Wimberger P, Lang S, Jochum S, Zeidler R. 2011. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol Immunother 60:639–648.
10. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sültmann H. 2011. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 128:608–616.
11. Bryniarski K, Ptak W, Jayakumar A, Püllmann K, Caplan MJ, Chairoungdua A, Lu J, Adams BD, Sikora E, Nazimek K. 2013. Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. J Allergy Clin Immunol 132:170–181. e179.
12. Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q, Yang Y, Wang L, Cao X, Wang J. 2012. Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol 188:5954–5961.
13. Carranza O, González Á. 2014. Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med 138:828.
14. Chen C-L, Lai Y-F, Tang P, Chien K-Y, Yu J-S, Tsai C-H, Chen H-W, Wu C-C, Chung T, Hsu C-W. 2012. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res 11:5611–5629.
15. Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F, Berens W, Wincovitch SM, Garfield SH, Leapman RD. 2006. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci USA 103:9903–9907.
16. Chen L, Charrier A, Zhou Y, Chen R, Yu B, Agarwal K, Tsukamoto H, Lee LJ, Paulaitis ME, Brigstock DR. 2014a. Epigenetic regulation of connective tissue growth factor by microRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. Hepatology 59:1118–1129.
17. Chen W-x, Liu X-m, Lv M-m, Chen L, Zhao J-h, Zhong S-l, Ji M-h, Hu Q, Luo Z, Wu J-z. 2014b. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS ONE 9:e95240.
18. Chen W-x, Zhong S-l, Ji M-h, Pan M, Hu Q, Lv M-m, Luo Z, Zhao J-h, Tang J-h. 2014c. MicroRNAs delivered by extracellular vesicles: An emerging resistance mechanism for breast cancer. Tumor Biol 35:2883–2892.
19. Cho JA, Park H, Lim EH, Lee KW. 2012. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int J Oncol 40:130–138.
20. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Mina PD, Menard S. 2012. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 227:658–667.
21. Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L. 2011. Intracellular and extracellular microRNAs in breast cancer. Clin Chem 57:18–32.
22. Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, Webb G, McDermott R, Watson W, Crown J. 2012. Docetaxel-resistance in prostate cancer: Evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS ONE 7:e50999.
23. Corrado C, Raimondo S, Saieva L, Flugy AM, De Leo G, Alessandro R. 2014. Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells. Cancer Lett 348:71–76.
24. De Wever O, Demetter P, Mareel M, Bracke M. 2008. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123:2229–2238.
25. Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, Mulders PF, Jannink SA, Schalken JA. 2014. Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol 191:1132–1138.
26. Duijvesz D, Burnum-Johnson KE, Gritsenko MA, Hoogland AM, Vredenbregt-van den Berg MS, Willemsen R, Luider T, Paša-Tolić L, Jenster G. 2013. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS ONE 8:e82589.
27. Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H. 2014. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 5:9650.
28. Eldh M, Bagge RO, Lässer C, Svanvik J, Sjöstrand M, Mattsson J, Lindnér P, Choi D-S, Gho YS, Lötvall J. 2014. MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma. BMC Cancer 14:962.
29. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ. 2012. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA 109:E2110–E2116.
30. Fathullahzadeh S, Mirzaei H, Honardoost M, Sahebkar A, Salehi M. 2016. Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Ther 23:327–332.
31. Gholamin S, Pasdar A, Khorrami MS, Mirzaei H, Mirzaei HR, Salehi R, Ferns GA, Ghayour-Mobarhan M, Avan A. 2016. The potential for circulating microRNAs in the diagnosis of myocardial infarction: A novel approach to disease diagnosis and treatment. Curr Pharm Des 22:397–403.
32. Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bigner DD. 2009. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J 23:1541–1557.
33. Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, Tetta C, Bussolati B, Camussi G. 2011. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 71:5346–5356.
34. Henderson MC, Azorsa DO. 2012. The genomic and proteomic content of cancer cell-derived exosomes. Front Oncol 2:38.
35. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. 2013. Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 13:714–726.
36. Hong BS, Cho J-H, Kim H, Choi E-J, Rho S, Kim J, Kim JH, Choi D-S, Kim Y-K, Hwang D. 2009. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 10:556.
37. Igney FH, Krammer PH. 2002. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 71:907–920.
38. Ishida T, Kiwada H. 2008. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 354:56–62.
39. Jang SC, Kim OY, Yoon CM, Choi D-S, Roh T-Y, Park J, Nilsson J, Lötvall J, Kim Y-K, Gho YS. 2013. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 7:7698–7710.
40. Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M. 2014. A comprehensive overview of exosomes as drug delivery vehicles—Endogenous nanocarriers for targeted cancer therapy. Biochim Biophys Acta 1846:75–87.
41. Katakowski M, Buller B, Zheng X, Lu Y, Rogers T, Osobamiro O, Shu W, Jiang F, Chopp M. 2013. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett 335:201–204.
42. Keller S, König A-K, Marmé F, Runz S, Wolterink S, Koensgen D, Mustea A, Sehouli J, Altevogt P. 2009. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett 278:73–81.
43. Khan S, Aspe J, Asumen M, Almaguel F, Odumosu O, Acevedo-Martinez S, De Leon M, Langridge W, Wall N. 2009. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer 100:1073–1086.
44. Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, Yuan Y, Wall NR. 2014. Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer 14:176.
45. Khan S, Jutzy JM, Valenzuela MMA, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR. 2012. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS ONE 7:e46737.
46. Klein-Scory S, Tehrani MM, Eilert-Micus C, Adamczyk KA, Wojtalewicz N, Schnölzer M, Hahn SA, Schmiegel W, Schwarte-Waldhoff I. 2014. New insights in the composition of extracellular vesicles from pancreatic cancer cells: Implications for biomarkers and functions. Proteome Sci 12:1–18.
47. Koch R, Demant M, Aung T, Diering N, Cicholas A, Chapuy B, Wenzel D, Lahmann M, Güntsch A, Kiecke C. 2014. Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma. Blood 123:2189–2198.
48. Kosaka N, Iguchi H, Yoshioka Y, Hagiwara K, Takeshita F, Ochiya T. 2012. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem 287:1397–1405.
49. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringnér M, Mörgelin M, Bourseau-Guilmain E, Bengzon J, Belting M. 2013. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci 110:7312–7317.
50. Lau C, Kim Y, Chia D, Spielmann N, Eibl G, Elashoff D, Wei F, Lin Y-L, Moro A, Grogan T. 2013. Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem 288:26888–26897.
51. Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. 2009. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 9:244.
52. Li Y, Zhang Y, Qiu F, Qiu Z. 2011. Proteomic identification of exosomal LRG1: A potential urinary biomarker for detecting NSCLC. Electrophoresis 32:1976–1983.
53. Lin J, Li J, Huang B, Liu J, Chen X, Chen X-M, Xu Y-M, Huang L-F, Wang X-Z. 2015. Exosomes: Novel biomarkers for clinical diagnosis. Scientific World J 2015:657086.
54. Loei H, Tan HT, Lim TK, Lim KH, So JB-Y, Yeoh KG, Chung MC. 2012. Mining the gastric cancer secretome: Identification of GRN as a potential diagnostic marker for early gastric cancer. J Proteome Res 11:1759–1772.
55. Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, Perdicchio M, Marino ML, Federici C, Iessi E. 2009. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS ONE 4:e5219.
56. Lopez-Verrilli MA. 2013. Exosomes: Mediators of communication in eukaryotes. Biol Res 46:5–11.
57. Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M, Wrana JL. 2012. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 151:1542–1556.
58. Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M, Giese NA, Kalthoff H, Becker T, Büchler MW. 2015. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer 136:2616–2627.
59. Maguire CA, Balaj L, Sivaraman S, Crommentuijn MH, Ericsson M, Mincheva-Nilsson L, Baranov V, Gianni D, Tannous BA, Sena-Esteves M. 2012. Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther 20:960–971.
60. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N. 2015. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523:177–182.
61. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA. 2014. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26:707–721.
62. Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji MM. 2015. Exosome mediated communication within the tumor microenvironment. J Control Release 219:278–294.
63. Mirzaei H, Darroudi M. 2017. Zinc oxide nanoparticles: Biological synthesis and biomedical applications. Ceram Int 43:907–914.
64. Mirzaei H, Gholamin S, Shahidsales S, Sahebkar A, Jafaari MR, Mirzaei HR, Hassanian SM, Avan A. 2016a. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur J Cancer 53:25–32.
65. Mirzaei H, Khoi M, Azizi M, Goodarzi M. 2016b. Can curcumin and its analogs be a new treatment option in cancer therapy? Cancer Gene Ther 23:410.
66. Mirzaei H, Sahebkar A, Avan A, Jaafari MR, Salehi R, Salehi H, Baharvand H, Rezaei A, Hadjati J, Pawelek JM. 2016c. Application of mesenchymal stem cells in melanoma: A potential therapeutic strategy for delivery of targeted agents. Curr Med Chem 23:455–463.
67. Mirzaei H, Sahebkar A, Jaafari M, Hadjati J, Javanmard S, Mirzaei H, Salehi R. 2016d. PiggyBac as a novel vector in cancer gene therapy: Current perspective. Cancer Gene Ther 23:45–47.
68. Mirzaei H, Sahebkar A, Yazdi F, Salehi H, Jafari M, Namdar A, Khabazian E, Jaafri M, Mirzaei H. 2016e. Circulating microRNAs in hepatocellular carcinoma: Potential diagnostic and prognostic biomarkers. Current Pharm Des. 22:5257–5269.
69. Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A. 2017. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother 85:102–112.
70. Mitchell PJ, Welton J, Staffurth J, Mason MD, Tabi Z, Clayton A. 2009. Can urinary exosomes act as treatment response markers in prostate cancer. J Transl Med 7:4.
71. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518.
72. Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, Ströbel T, Breakefield XO, Saydam O. 2013. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol Ther 21:101–108.
73. Mohammadi M, Goodarzi M, Jaafari M, Mirzaei H, Mirzaei H. 2016a. Circulating microRNA: A new candidate for diagnostic biomarker in neuroblastoma. Cancer Gene Ther 23:371–372.
74. Mohammadi M, Jaafari M, Mirzaei H, Mirzaei H. 2016b. Mesenchymal stem cell: A new horizon in cancer gene therapy. Cancer Gene Ther 23:285–286.
75. Mrizak D, Martin N, Barjon C, Jimenez-Pailhes A-S, Mustapha R, Niki T, Guigay J, Pancré V, de Launoit Y, Busson P. 2015. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. J Natl Cancer Inst 107:dju363.
76. Munoz JL, Bliss SA, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. 2013. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids 2:e126.
77. Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M, Lochnit G, Preissner KT, Zöller M. 2010. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res 70:1668–1678.
78. Nieuwland R, Van Der Post J, Lok C, Kenter G, Sturk A. 2010. Microparticles and exosomes in gynecologic neoplasias. Semin Thromb Hemost 36:925–929.
79. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield X, Widmark A. 2009. Prostate cancer-derived urine exosomes: A novel approach to biomarkers for prostate cancer. Br J Cancer 100:1603–1607.
80. Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H. 2014. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS ONE 9:e92921.
81. Ohno S-i, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, Fujita K, Mizutani T, Ohgi T, Ochiya T. 2013. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther 21:185–191.
82. Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, Watanabe Y, Muramatsu K, Fukuda Y, Ogura S-i, Yamaguchi K. 2010. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS ONE 5.
83. Olimón-Andalón V, Aguilar-Lemarroy A, Ratkovich-González S, Uribe-López A, Mariscal-Ramírez I, Delgadillo-Cristerna R, Ortiz-Lazareno P, Hernández-Flores G, de Celis R, Bravo-Cuellar A. 2015. Proapoptotic CD95L levels in normal human serum and sera of breast cancer patients. Tumor Biol 36:3669–3678.
84. Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B, Hendrix A, Lamy P, Dagnaes-Hansen F, Rasmussen MH. 2014. Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res 74:5758–5771.
85. Pan Q, Ramakrishnaiah V, Henry S, Fouraschen S, de Ruiter PE, Kwekkeboom J, Tilanus HW, Janssen HL, van der Laan LJ. 2011. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut 61:1330–1339.
86. Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W, Lim SK, Sze SK. 2010. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 9:1085–1099.
87. Park JO, Choi DY, Choi DS, Kim HJ, Kang JW, Jung JH, Lee JH, Kim J, Freeman MR, Lee KY. 2013. Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. Proteomics 13:2125–2134.
88. Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar CM. 2012. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18:883–891.
89. Perez A, Loizaga A, Arceo R, Lacasa I, Rabade A, Zorroza K, Mosen-Ansorena D, Gonzalez E, Aransay AM, Falcon-Perez JM. 2014. A pilot study on the potential of RNA-associated to urinary vesicles as a suitable non-invasive source for diagnostic purposes in bladder cancer. Cancers 6:179–192.
90. Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH. 2009. Exosomal microRNA: A diagnostic marker for lung cancer. Clin Lung Cancer 10:42–46.
91. Raimondo S, Saieva L, Corrado C, Fontana S, Flugy A, Rizzo A, De Leo G, Alessandro R. 2015. Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism. Cell Commun Signal 13:1.
92. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai Y-T, Reagan M, Azab F, Flores LM, Campigotto F, Weller E. 2013. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 123:1542–1555.
93. Rosell R, Wei J, Taron M. 2009. Circulating microRNA signatures of tumor-derived exosomes for early diagnosis of non-small-cell lung cancer. Clin Lung Cancer 10:8–9.
94. Runz S, Keller S, Rupp C, Stoeck A, Issa Y, Koensgen D, Mustea A, Sehouli J, Kristiansen G, Altevogt P. 2007. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecologic Oncol 107:563–571.
95. Saadatpour L, Fadaee E, Fadaei S, Mansour RN, Mohammadi M, Mousavi S, Goodarzi M, Verdi J, Mirzaei H. 2016. Glioblastoma: Exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther 23:415–418.
96. Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, Howell SB. 2005. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 4:1595–1604.
97. Salarini R, Sahebkar A, Mirzaei H, Jaafari M, Riahi M, Hadjati J, Asrami M, Fdaee S, Salehi R, Mirzaei H. 2015. Epi-drugs and Epi-miRs: Moving beyond current cancer therapies. Curr Cancer Drug Targets 16:773–778.
98. Schey KL, Luther JM, Rose KL. 2015. Proteomics characterization of exosome cargo. Methods 87:75–82.
99. Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, Hochberg FH, Breakefield XO, Weissleder R, Lee H. 2012. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med 18:1835–1840.
100. Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR. 2003. Expulsion of small molecules in vesicles shed by cancer cells association with gene expression and chemosensitivity profiles. Cancer Res 63:4331–4337.
101. Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV. 2013. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal 11:1186.
102. Silva J, García V, Zaballos A, Provencio M, Lombardía L, Almonacid L, García JM, Domínguez G, Peña C, Diaz R. 2011. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J 37:617–623.
103. Simonian M, Mosallayi M, Mirzaei H. 2016. Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker. Cancer Res Ther.
104. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Curry WT, Carter BS, Krichevsky AM, Breakefield XO. 2008. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470–1476.
105. Smalley DM, Sheman NE, Nelson K, Theodorescu D. 2008. Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res 7:2088–2096.
106. Stoeck A, Keller S, Riedle S, Sanderson MP, Runz S, Le Naour F, Gutwein P, Ludwig A, Rubinstein E, Altevogt P. 2006. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J 393:609–618.
107. Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, Hoffman RM. 2013. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev 65:383–390.
108. Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, Ueo H, Shinden Y, Iguchi T, Eguchi H, Shirabe K. 2015. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer 112:532–538.
109. Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, Barnes S, Grizzle W, Miller D, Zhang H-G. 2010. A novel nanoparticle drug delivery system: The anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 18:1606–1614.
110. Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y, Ikeda N, Isozaki Y, Maruyama T, Akanuma N. 2013. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer 108:644–652.
111. Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M, Watanabe M, Baba H. 2013. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 119:1159–1167.
112. Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott AM, Simpson RJ. 2012. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods 56:293–304.
113. Tavoosidana G, Ronquist G, Darmanis S, Yan J, Carlsson L, Wu D, Conze T, Ek P, Semjonow A, Eltze E. 2011. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci USA 108:8809–8814.
114. Taylor DD, Gercel-Taylor C. 2008. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110:13–21.
115. Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, Wei J, Nie G. 2014. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35:2383–2390.
116. Tickner JA, Urquhart AJ, Stephenson S-A, Richard DJ, O'Byrne KJ. 2014. Functions and therapeutic roles of exosomes in cancer. Front Oncol 4:127.
117. Umezu T, Ohyashiki K, Kuroda M, Ohyashiki J. 2013. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene 32:2747–2755.
118. Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH. 2014. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood 124:3748–3757.
119. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659.
120. van Dommelen SM, Vader P, Lakhal S, Kooijmans S, van Solinge WW, Wood MJ, Schiffelers RM. 2012. Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery. J Control Release 161:635–644.
121. Wahlgren J, Karlson TDL, Brisslert M, Sani FV, Telemo E, Sunnerhagen P, Valadi H. 2012. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res 40:e130.
122. Wang H, Hou L, Li A, Duan Y, Gao H, Song X. 2014. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int 2014.
123. Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. 2010. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 70:9621–9630.
124. Xin H, Li Y, Buller B, Katakowski M, Zhang Y, Wang X, Shang X, Zhang ZG, Chopp M. 2012. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells 30:1556–1564.
125. Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. 2015. Cancer nanomedicine: From targeted delivery to combination therapy. Trends Mol Med 21:223–232.
126. Yang C, Robbins PD. 2011. The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol 2011:842849.
127. Ye S-b, Li Z-L, Luo D-h, Huang B-j, Chen Y-S, Zhang X-s, Cui J, Zeng Y-x, Li J. 2014. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget 5:5439–5452.
128. Yong FL, Wang CW, Roslani AC, Law CW. 2014. The involvement of miR-23a/APAF1 regulation axis in colorectal cancer. Int J Mol Sci 15:11713–11729.
129. Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle WE. 2007. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 178:6867–6875.
130. Zhang J, Li S, Li L, Li M, Guo C, Yao J, Mi S. 2015a. Exosome and exosomal microRNA: Trafficking, sorting, and function. Genomics Proteomics Bioinformatics 13:17–24.
131. Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. 2015b. Exosomes in cancer: Small particle, big player. J Hematol Oncol 8:1–13.
132. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X. 2010. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 39:133–144.
133. Zhao L, Liu W, Xiao J, Cao B. 2015. The role of exosomes and “exosomal shuttle microRNA” in tumorigenesis and drug resistance. Cancer Lett 356:339–346.
134. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, Ju S, Mu J, Zhang L, Steinman L. 2011. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 19:1769–1779.